Vertex Presents New CASGEVY Data in Children, Expands Global Regulatory Filings
Vertex Pharmaceuticals presented new data showing positive outcomes with CASGEVY in children aged 5–11 with sickle cell disease or beta thalassemia and announced... Read more.
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
Orionis Biosciences and Novartis have expanded their strategic collaboration to discover and develop molecular glue medicines, leveraging Orionis’s AI-driven Allo-Glue... Read more.
UAE Approves New Oral Breast Cancer Treatment for Hormone-Resistant Cases
The UAE has approved AstraZeneca’s Etcamah, a new oral therapy for advanced breast cancer patients with ESR1 mutations, expanding treatment options for hormone-resistant... Read more.
PRCA MENA Launches 4th Annual Mental Health Survey
PRCA MENA has launched the fourth edition of its regional Mental Health Survey, inviting communications professionals across the Middle East and North Africa to... Read more.
LCRF and AstraZeneca Launch Research Awards to Advance Small Cell Lung Cancer Treatment
The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, has announced two new research funding opportunities aimed at improving outcomes for... Read more.
IBA Announces Research Collaboration to Strengthen Evidence on the Value of Proton Therapy
IBA has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to generate clinical and economic evidence supporting... Read more.
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy... Read more.
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), allowing eligible patients with moderate-to-severe atopic... Read more.
Asante partners with Western University of Health Sciences to launch core rotation sites for medical students
Asante has partnered with Western University of Health Sciences’ COMP-Northwest to establish new clinical rotation opportunities for third- and fourth-year osteopathic... Read more.
Harbour BioMed Announces NMPA Acceptance for the Treatment of Advanced Solid Tumors
Harbour BioMed has announced that China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for HBM7004,... Read more.
